2008-10-13 12:11:02 -

- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Everest Re Group, Ltd. (NYSE: RE), State Auto Financial Corp. (Nasdaq: STFC), Sangamo Biosciences, Inc. (Nasdaq: SGMO), Lloyds TSB Group Plc. (NYSE:

LYG) and HBOS Plc. (Nasdaq: HBOS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: at.zacks.com/?id=4579

Here are highlights from Friday's Analyst Blog:

Everest Re Peaks at a Hold

Everest Re Group, Ltd. (NYSE: RE) intends to release its 3Q08 earnings later this month. The company continues to experience rate pressures resulting from increased competition, higher commissions, and increased retentions by the ceding companies. Competition continues with a greater intensity in the US than in the international markets.

However, the company's results should be able to benefit from its strong risk-adjusted capitalization, good long-term operating performance, strong traditional risk management capabilities, well-diversified product lines and excellent market profile as a leading global reinsurance franchise, going forward. Even so, our Hold recommendation on the shares remains in place, presently.

State Auto Kept in Neutral

Headquartered in Columbus, Ohio, State Auto Financial Corporation (Nasdaq: STFC) is a property & casualty insurance holding company formed in June 1991 by State Automobile Mutual Insurance Company (Mutual), an Ohio mutual P&C company. Founded in 1921, Mutual currently owns approximately two-thirds of STFC.

STFC is expected to release its 3Q08 results on October 23, 2008. The company reported operating losses of $0.12 per share in 2Q08, versus operating net income of $0.51 per share in the prior year quarter, driven by a record level of catastrophe losses of $76.8 million.

Sangamo Biotech a Strong Buy

Sangamo Biosciences, Inc. (Nasdaq: SGMO) is a biopharmaceutical company engaging in designing and developing engineered transcription factors for gene regulation. The company uses a proprietary gene regulation technology to discover and develop a new class of therapeutic candidates for cardiovascular disease, cancer, neuropathic pain and immune diseases, such as sickle cell anemia and HIV.

Sangamo uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases. We are optimistic about this novel technology and are encouraged to hear that the company intends to bring more drug candidates into the clinic in 2008.

Lloyds a Hold on HBOS Buyout

We are maintaining our Hold on Lloyds TSB Group Plc (NYSE: LYG). The company has agreed to buy HBOS Plc (Nasdaq: HBOS), a UK bank with GBP 681 billion in total assets, in an all-stock deal worth about GBP 12 billion, expected to be completed in late 2008/early 2009.

We are reducing our 2008 EPADS estimate to $2.90 from $3.00, due to recent share issuance and US$ appreciation, and our 2009 estimate to $3.95 from $4.00, including the HBOS acquisition. While the deal makes Lloyds the #1 bank in the UK in terms of market share and over GBP 1 billion in pretax cost synergies are seen, risks include major loan concentrations, increased reliance on wholesale funding, and potential capital shortfalls.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at at.zacks.com/?id=4580.

Visit www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com